#152550

MCF7/LetR-4 Cell Line

Please Enter Your Email ID
Email ID

Cat. #152550

MCF7/LetR-4 Cell Line

Cat. #: 152550

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-5 days

Organism: Human

Tissue: Breast

Disease: Cancer

£800.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne Lykkesfeldt

Institute: Danish Cancer Society

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: MCF7/LetR-4 Cell Line
  • Cancer: Breast cancer
  • Cancers detailed: Breast cancer
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: MCF7
  • Organism: Human
  • Tissue: Breast
  • Disease: Cancer
  • Growth properties: Breast cancer cell line resistant to the aromatase inhibitor letrozole. Estrogen receptor positive.
  • Conditional: No
  • Description: The MCF7/LetR-4 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors. Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However, a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the non-steroidal AI letrozole allows the study of the molecular basis for resistance to AIs to unravel new targets for treatment.
  • Production details: Letrozole-resistant cell lines were established from MCF-7 cells grown in medium with 10% NCS and 10â?‚ˆ?‚Â’7 M testosterone. A culture of MCF-7 cells were treated with 10â?‚ˆ?‚Â’6 M letrozole for one week, trypsinized and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with letrozole. After ~2â?‚€?‚“3 months, the isolated colonies gave rise to letrozole-resistant cell lines, which could be grown in letr...
  • Biosafety level: 1
  • Cellosaurus id: CVCL_5A20

Target Details

  • Target: Letrozole resistant

Applications

  • Application notes: Human breast cancer cell line derived from MCF-7 cells Other related cell lines: - LetR-1, LetR-2 and LetR-3 resistant to the non-steroidal AI letrozole - ExeR-1, ExeR-2, ExeR-3 and ExeR-4 resistant to the steroidal AI exemestane - AnaR-1, AnaR-2, AnaR-3 and AnaR-4 resistant to the non-steroidal AI anastrozole Passage 436 (AL3183, AL3184)

Handling

  • Format: Frozen
  • Passage number: Passage 436 (AL3183, AL3184)
  • Growth medium: Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 1 uM letrozole.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

Related Tools

  • Related tools: MCF7/LetR-1 Cell Line ; MCF7/LetR-2 Cell Line ; MCF7/LetR-3 Cell Line Other related cell lines: - LetR-1, LetR-2 and LetR-3 resistant to the non-steroidal AI letrozole - ExeR-1, ExeR-2, ExeR-3 and ExeR-4 resistant to the steroidal AI exemestane - AnaR-1, AnaR-2, AnaR-3 and AnaR-4 resistant to the non-steroidal AI anastrozole

References

  • Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.
  • Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.
  • Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
  • New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.